DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$29.38
Market Cap
$4.02B
52W High
$49.70
52W Low
$10.47
ADV30
1,736,432
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -72,279,000 | -50,961,000 | 1,074,283,000 | 241,150,000 | 106,249,000 |
| Jun 2026 | 0 | — | -75,077,000 | -158,986,000 | 1,112,899,000 | 655,267,000 | 194,220,000 |
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-191,364,000
Investing CF
$-612,550,000
Financing CF
$1,025,107,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.39
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-869,717,000
Inventory
—
Receivables
—
ST Investments
$805,698,000
EBIT TTM
$-332,585,000
Pretax Income TTM
$-337,481,000
Interest Exp TTM
$4,896,000
Analysts
18
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | 332,327,000 | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | 241,448,000 | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | 78,134,000 | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | 150,917,000 | -50,139,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-353,785,000
OpCashFlow TTM
—
Assets (Latest)
$1,112,899,000
Forward EPS
$-1.80
Max Pain — expiry 2027-01-15
max pain strike: $15.00 · spot: $29.12 · call oi: 18,482 · put oi: 1,700Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVNT | AVIENT CORP | $3.99B | $43.54 | — |
| IPAR | INTERPARFUMS INC | $4.24B | $132.45 | — |
| CSW | CSW INDUSTRIALS, INC. | $4.39B | $269.38 | — |
| SMG | SCOTTS MIRACLE-GRO CO | $3.64B | $62.55 | — |
| CBT | CABOT CORP | $3.62B | $70.14 | — |
News headlines (Yahoo Finance, 1h cache)
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
2026-11-16 23:05 · Yahoo
Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
2026-11-12 08:09 · Yahoo
How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
2026-11-12 01:17 · Yahoo
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
2026-11-11 21:10 · Yahoo
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
2026-11-11 10:12 · Yahoo
Definium (DFTX) Q3 2026 Earnings Call Transcript
2026-11-10 02:00 · Yahoo
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
2026-11-10 01:14 · Yahoo
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 21:01 · Yahoo
Definium Therapeutics Announces New Employee Inducement Grants
2026-11-09 12:01 · Yahoo
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
2026-11-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.